Pre-IPO Financing and Overseas Market BD Collaboration for High-Certainty Biopharmaceutical Enterprises in Assisted Reproduction and Ophthalmology (Fundus) Fields
Supplier Advantages: Jingze Biopharmaceuticals (Hefei) Co., Ltd. focuses on the fields of assisted reproduction and ophthalmology, utilizing cutting-edge biotechnology for innovative research and development. The company has one product that has applied for NDA approval, which is expected to be granted in October 2024, and six other products at various clinical stages. The C+ round of financing has been completed, with a valuation reaching 2.9925 billion RMB. Plans include an IPO on the NEEQ by the end of 2024 and an H-share IPO in the first half of 2025. The company is seeking 200-300 million RMB in financing to advance product development and commercialization and hopes to collaborate with overseas partners to develop rights and channels for its R&D pipeline and NDA-submitted products.
| No data available |
1. Company Profile
Jingze Biopharmaceuticals (Hefei) Co., Ltd. (hereinafter referred to as "Jingze Bio") focuses on the fields of assisted reproduction and ophthalmology, committed to applying cutting-edge biotechnology for innovative research and development as well as industrialization, aiming to become a leading enterprise in these two fields in China.
2. Product Pipeline Progress
In the product pipeline of Jingze Bio, one product has applied for NDA (Recombinant Human Follicle-Stimulating Hormone for Injection (rh-FSH), expected to receive production approval in October 2024); three products have entered Phase III clinical trials; and three products have entered Phase I clinical trials.
3. Current Valuation and Financing Needs
C+ round financing was officially closed in March 2024 (RMB 380 million), entering the Pre-IPO stage, with a current valuation of RMB 2.9925 billion.
Financing needs: 200 million to 300 million RMB, mainly used to advance the clinical trial progress of products in the pipeline and the commercialization layout of related products.
4. IPO Planning (3+H)
Completed shareholding reform and IPO coaching. Brokerages, law firms, and accounting firms have been engaged. Plans for an NEEQ IPO by the end of 2024 and an H-share IPO in the first half of 2025.
5. BD Cooperation Intent
Seeking cooperation on overseas rights and channels for the company's current R&D products and NDA-submitted products.